mywebduck.typepad.com — The FDA recently took action on behalf of pharmaceutical manufacturer Wyeth to impose harmful restrictions on the compounding and dispensing of bio-identical hormone replacement therapy (BHRT), specifically compounded medicines containing the drug estriol. This action has critical implications for pharmacists, patients and physicians.